First Hospital of China Medical University
中国医科大学附属第一医院
Listed for 29 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at First Hospital of China Medical University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌5 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌7 papers led
- Hepatocellular carcinoma肝细胞癌61 papers led2 open trials led
- Stomach cancer胃癌109 papers led1 open trial led
- Chordoma脊索瘤0 papers led
- Osteosarcoma骨肉瘤5 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤6 papers led
- Neuroblastoma神经母细胞瘤2 papers led
- Ewing sarcoma尤文肉瘤1 paper led
- Multiple myeloma多发性骨髓瘤4 papers led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
- Haemophilia A血友病 A1 paper led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病6 papers led
- IgG4-related diseaseIgG4相关性疾病6 papers led
- Myasthenia gravis重症肌无力9 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
- Takayasu arteritis大动脉炎0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
- Fabry disease法布雷病0 papers led
- Duchenne muscular dystrophy杜氏肌营养不良1 paper led
- IgA nephropathyIgA 肾病4 papers led
- Osteogenesis imperfecta成骨不全症1 paper led
- Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
- Primary sclerosing cholangitis原发性硬化性胆管炎2 papers led
- Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led
- Hereditary angioedema遗传性血管性水肿0 papers led
Not listed for: Hepatoblastoma, Retinoblastoma, Aplastic anaemia, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Moyamoya disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Hirschsprung disease, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shenyang for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led5
- PTEN as a prognostic factor for radiotherapy plus immunotherapy response in nasopharyngeal carcinoma.
- CAPRIN1/TYMS/MTHFD2 axis promotes EMT process in nasopharyngeal carcinoma development.
- Chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Who really needs it.
- Efficacy and toxicities of elective upper-neck irradiation versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: A meta-analysis.
- Effects of Baduanjin exercise in nasopharyngeal carcinoma patients after chemoradiotherapy: a randomized controlled trial.
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)5
- Assessment Tools for Health‐Related Quality of Life in Patients With Nasopharyngeal Carcinoma: A Systematic Review of Psychometric Properties
- ctDNA-guided treatment stratification for nasopharyngeal carcinoma patients: A retrospective cohort.
- Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway
- Additional file 1 of Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis
- MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 7 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shenyang for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led7
- Screening and verification of hub genes in esophageal squamous cell carcinoma by integrated analysis.
- PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis.
- Mucosal esophageal carcinoma following endoscopic submucosal dissection with giant gastric metastasis: A case report and review of literature.
- circRNA_141539 can serve as an oncogenic factor in esophageal squamous cell carcinoma by sponging miR-4469 and activating CDK3 gene.
- LncRNA LINC00467 acted as an oncogene in esophageal squamous cell carcinoma by accelerating cell proliferation and preventing cell apoptosis via the miR-485-5p/DPAGT1 axis.
- High expression of CIN85 promotes proliferation and invasion of human esophageal squamous cell carcinoma.
- Clinical analysis of 117 cases with synchronous multiple primary esophageal squamous cell carcinomas.
All its trials on ClinicalTrials.gov, any status3
- Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma
More papers found outside PubMed (not counted)26
- 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma
- An organ-preserving strategy in patients with esophageal squamous cell carcinoma treated with immunochemotherapy.
- 418P A PET/CT image-based deep learning approach for precise survival prognosis and clinical management of treatments in patients with esophageal carcinoma
- The intricate mechanism through which UMODL1 accelerating tumor proliferation of Her-2 positive breast cancer as well as trastuzumab resistance
- 1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Proper prognostic classification of histopathologic response to neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma
- Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF1
- Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma
- Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial
- Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an
- RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling
Cancer
Hepatocellular carcinoma
肝细胞癌Led 61 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.
4 hospitals in Shenyang for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 7
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingConversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07483359
Age 18 years to 80 years (registered criteria)
Led by First Hospital of China Medical UniversityShenyang
- Not yet recruitingEpalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07557914
Age 18 years to 80 years (registered criteria)
Led by First Hospital of China Medical UniversityShenyang
- RecruitingFirst in Human Study of SIM0610 in Solid Tumors
- Phase
- Phase 1
- Started
- 2026-01
- Registry
- NCT07348211
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang
- RecruitingJS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06954467
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou
- RecruitingStudy to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07239245
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesBeijing, Shenyang, Zhengzhou
- RecruitingABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07327034
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou
- RecruitingCT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- Phase
- Phase 1
- Started
- 2023-10
- Registry
- NCT06560827
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led61
- Non-Gaussian diffusion MRI models for preoperative assessment of microvascular invasion in hepatocellular carcinoma.
- G6PD+CSV+ circulating tumor cells associated with portal vein tumor thrombus formation via EMT-ferroptosis crosstalk: a dual biomarker for therapeutic efficacy and prognosis prediction in hepatocellular carcinoma.
- Suppressing hyperthermia-induced up-regulated PD-L1 with a Sunitinib loaded Fe-Cu MOF: Strengthening immunogenic cell death to sensitize anti-PD-L1 effect following microwave ablation of hepatocellular carcinoma.
- Research progress and therapeutic strategies in hepatocellular carcinoma metabolic reprogramming.
- Balloon-occluded versus conventional transarterial chemoembolization for the treatment of early to intermediate stage hepatocellular carcinoma: a meta-analysis and trial sequential analysis.
- Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumour burden and portal vein tumour thrombus (CHANCE 2416): st
- The multifaceted roles of macrophages in the transition from hepatitis to hepatocellular carcinoma: From mechanisms to therapeutic strategies.
- Transcriptional regulation of ATOX1 by PRRX2 impacts the progression and cuproptosis of hepatocellular carcinoma.
- Complications of transarterial radioembolization in hepatic malignancies: Pathophysiological insights and management paradigms.
- CD63-high macrophage-derived exosomal miR-6876-5p promotes hepatocellular carcinoma stemness via PTEN/Akt-mediated EMT pathway.
- In vitro anticancer effects in hepatocellular carcinoma (HCC) and protein interaction study of xanthoangelol.
- MRI-based radiomics predicts complete responses to initial transcatheter arterial chemoembolization in virus-associated early and intermediate stage HCC.
- Predicting the outcome of transarterial chemoembolization combined with targeted immunotherapy for unresectable hepatocellular carcinoma based on MRI radiomics.
- NELL2 suppresses epithelial-mesenchymal transition and induces ferroptosis via notch signaling pathway in HCC.
- Artificial intelligence in hepatopathy diagnosis and treatment: Big data analytics, deep learning, and clinical prediction models.
- Deep Learning Model for Predicting Proliferative Hepatocellular Carcinoma Using Dynamic Contrast-Enhanced MRI: Implications for Early Recurrence Prediction Following Radical Resection.
- CD63 + tumor-associated macrophages drive the progression of hepatocellular carcinoma through the induction of epithelial-mesenchymal transition and lipid reprogramming.
- Long Noncoding RNAs MALAT1 and HOTTIP Act as Serum Biomarkers for Hepatocellular Carcinoma.
- The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions.
- Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.
- TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis.
- The hepatic steatosis, steatohepatitis and metabolic dysfunction: distinct roles in hepatocellular carcinoma occurrence in chronic hepatitis B patients.
- Identification of PPAR-related differentially expressed genes liver hepatocellular carcinoma and construction of a prognostic model based on data analysis and molecular docking.
- Hemoglobin nanoclusters-mediated regulation of KPNA4 in hypoxic tumor microenvironment enhances photodynamic therapy in hepatocellular carcinoma.
- Identification of an m6A Natural Inhibitor, Lobeline, That Reverses Lenvatinib Resistance in Hepatocellular Tumors.
- Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
- Nicotinamide mononucleotide induces autophagy and ferroptosis via AMPK/mTOR pathway in hepatocellular carcinoma.
- Multimodal Theranostic Nanoparticles for Necrosis Targeting, Fluorescence/SPECT Imaging, and Radiotherapy of Residual Tumors after Hepatocellular Carcinoma Ablation.
- Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
- Reserpine, a novel N6-methyladenosine regulator, reverses Lenvatinib resistance in hepatocellular carcinoma.
- Cell division cycle-associated 8 is a prognostic biomarker related to immune invasion in hepatocellular carcinoma.
- Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.
- Survival benefit of perioperative locoregional adjuvant treatment for hepatocellular carcinoma with portal vein tumor thrombosis: A systematic review and Bayesian network meta-analysis.
- Efficacy and safety of CalliSpheres® microspheres drug-eluting beads transarterial chemoembolization in GCLM combined trans-arterial infusion therapy for treating primary focus of gastric cancer: a multi-center retrospective study.
- Characterizing ligand-receptor interactions and unveiling the pro-tumorigenic role of CCL16-CCR1 axis in the microenvironment of hepatocellular carcinoma.
- Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib.
- CDK1-SRC Interaction-Dependent Transcriptional Activation of HSP90AB1 Promotes Antitumor Immunity in Hepatocellular Carcinoma.
- Significant CircRNAs in liver cancer stem cell exosomes: mediator of malignant propagation in liver cancer?
- SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.
- Nomogram-based development and evaluation for predictions of 30-day and 1-year survival in patients with spontaneously ruptured hepatocellular carcinoma.
- Tumor and peritumor radiomics analysis based on contrast-enhanced CT for predicting early and late recurrence of hepatocellular carcinoma after liver resection.
- miR-3168 promotes hepatocellular carcinoma progression via downregulating p53.
- miR-3154 promotes hepatocellular carcinoma progression via suppressing HNF4α.
- Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis.
- Predicting Prognosis of Hepatocellular Carcinoma Patients Based on the Expression Signatures of Mitophagy Genes.
- Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma.
- A novel m6A-related prognostic signature for predicting the overall survival of hepatocellular carcinoma patients.
- Mig-6 Inhibits Autophagy in HCC Cell Lines by Modulating miR-193a-3p.
- Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review).
- Identification of the Mechanism of Matrine Combined with Glycyrrhizin for Hepatocellular Carcinoma Treatment through Network Pharmacology and Bioinformatics Analysis.
- Evaluation of the efficacy and postoperative outcomes of hydrodissection-assisted microwave ablation for subcapsular hepatocellular carcinoma and colorectal liver metastases.
- Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study.
- Brachytherapy with Iodine-125 seeds for treatment of portal vein-branch tumor thrombus in patients with hepatocellular carcinoma.
- Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice.
- Aloin decelerates the progression of hepatocellular carcinoma through circ_0011385/miR-149-5p/WT1 axis.
- MicroRNA-1178-3p suppresses the growth of hepatocellular carcinoma by regulating transducin (beta)-like 1 X-linked receptor 1.
- Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
- Impact of low serum hemoglobin on development of contrast-induced nephropathy (CIN) in patients with hepatocellular carcinoma (HCC) following transarterial chemoembolisation (TACE).
- Nanomedicine Approach to Immunotherapy of Hepatocellular Carcinoma.
- Identification of CD8+ T Cell-Related Genes: Correlations with Immune Phenotypes and Outcomes of Liver Cancer.
- Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis: A case report and literature review.
All its trials on ClinicalTrials.gov, any status17
- Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
- HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
- HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC
- HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
- Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
- Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
- First in Human Study of SIM0610 in Solid Tumors
- Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
- JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
- A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
- Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC
- A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
Cancer
Stomach cancer
胃癌Led 109 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.1%.
5 hospitals in Shenyang for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 10
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingSHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06666166
Age 18 years to 75 years (registered criteria)
Led by First Hospital of China Medical UniversityShenyang
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingNanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06830018
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang
- RecruitingClinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2024-09
- Registry
- NCT06128252
Age 18 years to 75 years (registered criteria)
Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an
- RecruitingTo Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2024-08
- Registry
- NCT06504732
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shenyang
- RecruitingA Phase 2 Clinical Study of ABSK061 and ABSK043
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06632262
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingAI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- Phase
- Not given
- Started
- 2023-09
- Registry
- NCT06035250
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou
- RecruitingA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2022-01
- Registry
- NCT05150691
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- RecruitingOGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
- Phase
- N/A
- Started
- 2022-09
- Registry
- NCT05450835
Age 18 years to 75 years (registered criteria)
Led by Nanfang Hospital; 7 listed hospitals as study sitesChangchun, Changsha, Guangzhou, Shantou, Shenyang
- RecruitingStudy of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2021-06
- Registry
- NCT04900818
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led109
- Targeting the SOX9/TIMP1 Axis with iRGD-Conjugated Nanoplatform Enhances Dendritic Cell Function and Photodynamic Immunotherapy in Gastric Cancer.
- Comparative short-term outcomes of peri-operative immunotherapy and targeted therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.
- Gastric cancer causing Schnitzler's metastasis: case report and systematic review of the features.
- Frailty as a predictor of postoperative outcomes in older gastroesophageal cancer patients: a systematic review and meta-analysis.
- Helicobacter pylori SlyD stabilizes TPT1 via hnRNPK and enhances OCT1-mediated CDX2 transcriptional activation to drive gastric intestinal metaplasia.
- Advanced ensemble staking model employing cfDNA fragmentation for early detection of esophageal and gastric cancer.
- De-ubiquitinase USP35 promotes peritoneal dissemination of gastric cancer by regulating metabolic reprogramming.
- Phytosphingosine suppresses gastric cancer through SFRP4/β-catenin axis-mediated Wnt signaling pathway inhibition.
- Development of a Risk Prediction Model for Preoperative Pre-Frailty in Elderly Patients with Gastric Cancer.
- Comprehensive Analysis of the ADCY Family and Identification of ADCY5 as a Prognostic Marker for Gastric Cancer.
- Prognostic performance of examined lymph nodes, lymph node ratio, and positive lymph nodes in gastric cancer: a competing risk model study.
- Immune analysis according to Lauren type for gastric cancer and its significance in individual treatment and prognostic prediction.
- Comprehensive pan-cancer analysis of USP35 and validation of its role in gastric cancer.
- Microsatellite-Stable Gastric Cancer Can be Classified into 2 Molecular Subtypes with Different Immunotherapy Response and Prognosis Based on Gene Sequencing and Computational Pathology.
- Primary solitary fibrous tumor of the stomach: A case report and a review of literature.
- Advances in 16S rRNA-Based Microbial Biomarkers for Gastric Cancer Diagnosis and Prognosis.
- T-bet+CD8+ T cells govern anti-PD-1 responses in microsatellite-stable gastric cancers.
- The interplay between oxytocin receptor and YAP in regulating gastric cancer progression.
- Machine learning reveals glycolytic key gene in gastric cancer prognosis.
- Overexpression of CAD in stomach adenocarcinoma tissues and its clinical significance.
- Gastric Cancer Models Developed via GelMA 3D Bioprinting Accurately Mimic Cancer Hallmarks, Tumor Microenvironment Features, and Drug Responses.
- Nanomechanical Analysis of Living Small Extracellular Vesicles to Identify Gastric Cancer Cell Malignancy Based on a Biomimetic Peritoneum.
- Frailty as a predictor of adverse outcomes in patients with gastric cancer: A systematic review and meta-analysis of 75,357 patients.
- Integrating transcriptomic data and digital pathology for NRG-based prediction of prognosis and therapy response in gastric cancer.
- Radiomics analysis in predicting vascular invasion in gastric cancer based on enhanced CT: a preliminary study.
- Effect of prehabilitation for patients undergoing gastric cancer surgery: a protocol of a systematic review and meta-analysis.
- Mechanisms of HIF1A-mediated immune evasion in gastric cancer and the impact on therapy resistance.
- Interpretable multi-modal artificial intelligence model for predicting gastric cancer response to neoadjuvant chemotherapy.
- Deep learning and machine learning approaches to classify stomach distant metastatic tumors using DNA methylation profiles.
- Causal relationships between coffee intake, apolipoprotein B and gastric, colorectal, and esophageal cancers: univariable and multivariable Mendelian randomization.
- LOXL1 promotes gastric cancer progression by β-catenin-cyclinD mediated proliferation.
- Case report: A case of rare metastasis of gastric cancer to the axillary lymph node metastasis treated with combination immunotherapy.
- TM-Score predicts immunotherapy efficacy and improves the performance of the machine learning prognostic model in gastric cancer.
- A bibliometric analysis of gastric cancer liver metastases: advances in mechanisms of occurrence and treatment options.
- Exploring new frontiers: cell surface vimentin as an emerging marker for circulating tumor cells and a promising therapeutic target in advanced gastric Cancer.
- Gastric intestinal metaplasia: progress and remaining challenges.
- Hypoxia-induced LAMB2-enriched extracellular vesicles promote peritoneal metastasis in gastric cancer via the ROCK1-CAV1-Rab11 axis.
- Prognostic and predictive value of pathohistological features in gastric cancer and identification of SLITRK4 as a potential biomarker for gastric cancer.
- Circulating long noncoding RNA, Zfpm2-As1, and XIST based on medical data analysis are potential plasma biomarkers for gastric cancer diagnosis.
- Alternative Splicing Factor Heterogeneous Nuclear Ribonucleoprotein U as a Promising Biomarker for Gastric Cancer Risk and Prognosis with Tumor-Promoting Properties.
- Comment on: Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).
- CRIP1 Reshapes the Gastric Cancer Microenvironment to Facilitate Development of Lymphatic Metastasis.
- Individualized Choice of Simultaneous Cholecystectomy in Patients with Gastric Cancer: A Systematic Review and Meta-analysis.
- ASO Author Reflections: The Safety Analysis and Potential Indications of Simultaneous Cholecystectomy for Gastric Cancer.
- Association of perioperative allogeneic blood transfusions and long-term outcomes following radical surgery for gastric and colorectal cancers: systematic review and meta-analysis of propensity-adjusted observational studies.
- Expression characteristics and their functional role of IGFBP gene family in pan-cancer.
- Long noncoding RNA PSMA3-AS1 functions as a competing endogenous RNA to promote gastric cancer progression by regulating the miR-329-3p/ALDOA axis.
- Characterization of RNA modifications in gastric cancer to identify prognosis-relevant gene signatures.
- Towards an optimal model for gastric cancer peritoneal metastasis: current challenges and future directions.
- Separation and single-cell analysis for free gastric cancer cells in ascites and peritoneal lavages based on microfluidic chips.
- Efficacy and safety of CalliSpheres® microspheres drug-eluting beads transarterial chemoembolization in GCLM combined trans-arterial infusion therapy for treating primary focus of gastric cancer: a multi-center retrospective study.
- Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis.
- Prognostic values of myosteatosis for overall survival in patients with gastric cancers: A meta-analysis with trial sequential analysis.
- circDYRK1A tethers biological behaviors of gastric carcinoma using novel bioinformatics analysis and experimental validations.
- Deep Learning-Based Stratification of Gastric Cancer Patients from Hematoxylin and Eosin-Stained Whole Slide Images by Predicting Molecular Features for Immunotherapy Response.
- FN1 mRNA 3'-UTR supersedes traditional fibronectin 1 in facilitating the invasion and metastasis of gastric cancer through the FN1 3'-UTR-let-7i-5p-THBS1 axis.
- Leveraging existing 16S rRNA microbial data to identify diagnostic biomarker in Chinese patients with gastric cancer: a systematic meta-analysis.
- Effect of Chemoradiotherapy on the Survival of Resectable Gastric Cancer Patients: A Systematic Review and Meta-Analysis.
- ASO Author Reflections: Chemoradiotherapy Versus Chemotherapy, Which One Is Better for Resectable Gastric Cancer Patients?
- ASO Author Reflections: Clinical Research and Application Prospect of HIPEC Combined with Surgery in Advanced Gastric Cancer.
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages.
- Abnormally Expressed lncRNAs as Potential Biomarkers for Gastric Cancer Risk: A Diagnostic Meta-Bioinformatics Analysis.
- Hsa_circ_0005230 is up-regulated and promotes gastric cancer cell invasion and migration via regulating the miR-1299/RHOT1 axis.
- RBMS1 promotes gastric cancer metastasis through autocrine IL-6/JAK2/STAT3 signaling.
- Gastric Organoids: Progress and Remaining Challenges.
- Kang-Ai Injection Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 Pathway.
- HER2-Negative Schnitzler Metastasis to the Rectum Detected Using 18 F-FDG PET/CT.
- Discordant Metabolic Response on 18F-FDG PET/CT in Synchronous Primary Gastric Lymphoma and Gastric Adenocarcinoma.
- Site-Specific Hypermethylation of SST 1stExon as a Biomarker for Predicting the Risk of Gastrointestinal Tract Cancers.
- Identification of RFX5 as prognostic biomarker and associated with immune infiltration in stomach adenocarcinoma.
- Predicting functional circular RNA-based competitive endogenous RNA network in gastric carcinoma using novel bioinformatics analysis.
- PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis.
- Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration.
- Sarcopenia and a 5-mRNA risk module as a combined factor to predict prognosis for patients with stomach adenocarcinoma.
- RBPMS2, as a novel biomarker for predicting lymph node metastasis, guides therapeutic regimens in gastric cancer.
- Involvement of CXCL17 and GPR35 in Gastric Cancer Initiation and Progression.
- GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma.
- Identification of specific role of SNX family in gastric cancer prognosis evaluation.
- Primary gastric melanoma with pancreatic metastasis: a case report.
- Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature.
- Central lymph node metastasis is predictive of survival in advanced gastric cancer patients treated with D2 lymphadenectomy.
- Ubiquitin-associated protein 2 like (UBAP2L) enhances growth and metastasis of gastric cancer cells.
- High expression of COL5A2, a member of COL5 family, indicates the poor survival and facilitates cell migration in gastric cancer.
- Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling.
- Circ_0049447 acts as a tumor suppressor in gastric cancer through reducing proliferation, migration, invasion, and epithelial-mesenchymal transition.
- Different clinicopathologic features and prognostic significance of signet ring cell histology in early and locally advanced gastric cancer patients.
- Inhibitors Targeting YAP in Gastric Cancer: Current Status and Future Perspectives.
- Prognostic significance of palliative gastrectomy in incurable advanced gastric cancer: a retrospective cohort study and meta-analysis.
- Differentiated/undifferentiated mixed type is a prognostic factor for T2/T3 gastric cancer patients.
- Mutations of key driver genes in gastric cancer metastasis risk: a systematic review and meta-analysis.
- Bufalin inhibits peritoneal dissemination of gastric cancer through endothelial nitric oxide synthase-mitogen-activated protein kinases signaling pathway.
- A Dynamic Transcriptome Map of Different Tissue Microenvironment Cells Identified During Gastric Cancer Development Using Single-Cell RNA Sequencing.
- Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature.
- Pepsinogen C expression-related lncRNA/circRNA/mRNA profile and its co-mediated ceRNA network in gastric cancer.
- Expression profiles and prognostic roles of m6A writers, erasers and readers in gastric cancer.
- PDCD4 regulates apoptosis in human peritoneal mesothelial cells and promotes gastric cancer peritoneal metastasis.
- Integrative analysis-based identification and validation of a prognostic immune cell infiltration-based model for patients with advanced gastric cancer.
- Hsa_circ_001988 attenuates GC progression in vitro and in vivo via sponging miR-197-3p.
- The m6A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of gastric cancer by regulating the PI3K/AKT/mTOR signaling pathway.
- Increased Expression of LIPC Is Associated with Aggressive Phenotype of Borrmann Type 4 Gastric Cancer.
- LINC00242/miR-1-3p/G6PD axis regulates Warburg effect and affects gastric cancer proliferation and apoptosis.
- Identifying Diagnostic and Prognostic Biomarkers and Candidate Therapeutic Drugs of Gastric Cancer Based on Transcriptomics and Single-Cell Sequencing.
- Comparative efficacy of treatments for previously treated patients with advanced esophageal and esophagogastric junction cancer: A network meta-analysis.
- Construction of an immune-related gene signature to predict survival and treatment outcome in gastric cancer.
- Positive lymph node ratio is an index in predicting prognosis for remnant gastric cancer with insufficient retrieved lymph node in R0 resection.
- Tumor-derived extracellular vesicles containing microRNA-1290 promote immune escape of cancer cells through the Grhl2/ZEB1/PD-L1 axis in gastric cancer.
- Circular RNA circVAPA promotes chemotherapy drug resistance in gastric cancer progression by regulating miR-125b-5p/STAT3 axis.
- A novel prognostic model based on epithelial-mesenchymal transition-related genes predicts patient survival in gastric cancer.
- An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer.
Chinese-language papers (not in the count)5
- [Progress of individualized precision therapy for peritoneal metastasis in gastric cancer].
- [Integrated diagnosis and treatment of peritoneal metastasis in gastric cancer].
- [Call for attention to the value and challenge of liquid biopsy in diagnosis and treatment for peritoneal metastasis of gastric cancer].
- [Recent progress and future prospects of treatment for peritoneal metastasis in gastric cancer].
- [Standardized implementation of minimally invasive surgery for Siewert Ⅱ esophagogastric junction adenocarcinoma].
All its trials on ClinicalTrials.gov, any status35
- Detection of CTC and ctDNA in the Diagnosis of Metastasis in Gastric Cancer
- Gut Microbiota and Metabonomics
- EDLS-clips in Endoscopic Full-thickness Resection
- Multi-center and Multi-modal Deep Learning Study of Gastric Cancer
- SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
- A Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Gastric Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing Method
- Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
- Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer
- Sensitivity and Specificity of NGS in Detecting bMSI in Patients With Gastric, Duodenal and Small Intestinal Cancer
- S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
- A Phase 2 Clinical Study of ABSK061 and ABSK043
- Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
- To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
- AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
- Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
- Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
- IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery
- A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
- A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer
Cancer
Chordoma
脊索瘤Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Shenyang for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)6
- Clinical classification of clival chordomas for transnasal approaches.
- Clinicopathological implications of TIM3+ tumor-infiltrating lymphocytes and the miR-455-5p/Galectin-9 axis in skull base chordoma patients.
- The Degree of Middle and Lower Clivus Invasion by Chordoma is Linked to Patient Prognosis Via Ki-67 Value.
- C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
- Comparison of the Effectiveness of Radiotherapy with Photons and Particles for Chordoma After Surgery: A Meta-Analysis.
- Clinical Application of Multimodal Neuronavigation System in Neuroendoscope-Assisted Skull Base Chordoma Resection.
Cancer
Osteosarcoma
骨肉瘤Led 5 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Shenyang for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led5
- FDG PET/CT in a Case of Primary Ewing Sarcoma of the Uterus.
- Mitochondria in skeletal system-related diseases.
- Construction and validation of an oxidative-stress-related risk model for predicting the prognosis of osteosarcoma.
- A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019.
- The inhibitory effect of CTAB on human osteosarcoma through the PI3K/AKT signaling pathway.
Earlier papers (2016–2020)11
- Carboxypeptidase E-ΔN promotes migration, invasiveness, and epithelial-mesenchymal transition of human osteosarcoma cells via the Wnt-β-catenin pathway.
- Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.
- LPS promote Osteosarcoma invasion and migration through TLR4/HOTAIR.
- Marital Status and Survival in Osteosarcoma Patients: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database.
- Effect of lncRNA ANRIL knockdown on proliferation and cisplatin chemoresistance of osteosarcoma cells in vitro.
- Cell division cycle 20 promotes cell proliferation and invasion and inhibits apoptosis in osteosarcoma cells.
- Knockdown of pyruvate kinase type M2 suppresses tumor survival and invasion in osteosarcoma cells both in vitro and in vivo.
- Long non-coding RNA NEAT1 promotes proliferation, migration and invasion of human osteosarcoma cells.
- X-linked inhibitor of apoptosis protein inhibitor Embelin induces apoptosis via PI3K/Akt pathway and inhibits invasion in osteosarcoma cells.
- MicroRNA‑106a regulates the proliferation and invasion of human osteosarcoma cells by targeting VNN2.
- MicroRNA-21 promotes proliferation, invasion and suppresses apoptosis in human osteosarcoma line MG63 through PTEN/Akt pathway.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 6 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Shenyang for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led6
- The efficacy of immunotherapy in the treatment of tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors: a systematic review and meta-analysis.
- Age-dependent diminution of female prognostic advantage in gastrointestinal stromal tumors: a retrospective cohort analysis.
- Impact of Gastrointestinal Bleeding on Prognosis and Associated Risk Factors in Gastrointestinal Stromal Tumors: A Systematic Review and Meta-Analysis.
- The first case of a collision tumor of gastrointestinal stromal tumor and intravascular large B cell lymphoma.
- Sarcopenia as a novel prognostic factor in the patients of primary localized gastrointestinal stromal tumor.
- Genomic Study of Chinese Quadruple-negative GISTs Using Next-generation Sequencing Technology.
Earlier papers (2016–2020)5
- Is endoscopic resection more effective than laparoscopic resection in gastric gastrointestinal stromal tumours?
- What is the clinical significance of the multivariate prediction model for GI stromal tumors with high malignant potential before endoscopic resection?
- The epithelioid gastrointestinal stromal tumor with pulmonary metastasis: A rare case report and literature review.
- Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
- The assessment of different risk classification systems for gastrointestinal stromal tumors (GISTs): the analytic results from the SEER database.
Cancer
Neuroblastoma
神经母细胞瘤Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Shenyang for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Cancer
Ewing sarcoma
尤文肉瘤Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Shenyang for Ewing sarcoma139 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 4 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.
- Open trials led
- 0
- recruiting or about to
2 hospitals in Shenyang for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07477587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Registry
- NCT04973605
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021.
- Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis.
- Megalosplenia as an initial manifestation of multiple myeloma with a novel CYLD gene mutation: A case report and literature review.
- A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients.
All its trials on ClinicalTrials.gov, any status9
- A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- A Study of Ninlaro in Real World Clinical Practice in China
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Shenyang for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia
No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
- Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
- Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Shenyang for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07208058
Age 16 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Haemophilia A
血友病 ALed 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Shenyang for haemophilia A160 hospitals in China for haemophilia A
No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shenyang for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 6 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Shenyang for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06413654
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou
- Not yet recruitingCrisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
- Phase
- Phase 4
- Started
- 2026-06
- Registry
- NCT07699770
Age 18 years to 75 years (registered criteria)
Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changchun, Chongqing, Kunming, Shenyang, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led6
- Distinct Inflammatory Profiles and Clinical Characteristics of NMOSD: A Comparative Analysis with NMOSD-like and Encephalitis-like MOG-AD.
- Effect of L-Carnitine Level on the Risk of Neuromyelitis Optica Spectrum Disorders: A Two-Sample Mendelian Randomization Study.
- Blood-based inflammatory protein biomarker panel for the prediction of relapse and severity in patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
- Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases.
- Retina thickness in clinically affected and unaffected eyes in patients with aquaporin-4 immunoglobulin G antibody seropositive neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.
- Field synopsis and systematic meta-analyses of genetic association studies in neuromyelitis optica.
All its trials on ClinicalTrials.gov, any status2
More papers found outside PubMed (not counted)1
Other diseases
IgG4-related disease
IgG4相关性疾病Led 6 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 2.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shenyang for IgG4-related disease46 hospitals in China for IgG4-related disease
No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led6
- Imaging therapeutic response to immunosuppression in IgG4-related coronary disease: The role of coronary wall enhancement cardiovascular magnetic resonance.
- Clinical characteristics and multimodal imaging insights of coronary involvement in immunoglobulin G4-related disease.
- Coronary artery wall contrast enhancement imaging impact on disease activity assessment in IgG4-RD: a direct marker of coronary involvement.
- Clinical features and relapse risks factors of IgG4 related disease: a single-center retrospective study.
- IgG4-Related Disease With Gastrointestinal Involvement: Case Reports and Literature Review.
- A Rare Manifestation of IgG4-Related Disease and Concurrent Idiopathic Hypereosinophilic Syndrome as Extensive Gastrointestinal Lesions: A Case Report.
Other diseases
Myasthenia gravis
重症肌无力Led 9 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 1.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shenyang for myasthenia gravis93 hospitals in China for myasthenia gravis
No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led9
- Machine Learning-Based Risk Assessment of Myasthenia Gravis Onset in Thymoma Patients and Analysis of Their Correlations and Causal Relationships.
- Beyond the Surface: Investigating the Potential Mechanisms of Non-Motor Symptoms in Myasthenia Gravis.
- Differential expression profiles of lncRNAs and a preliminary study on the mechanism of lncRNA FAM225A in triple seronegative myasthenia gravis.
- Telitacicept as double-targeted therapy for myasthenia gravis coexisting with connective tissue disease: three case reports.
- Efgartigimod Is an Effective Treatment for Triple-Seronegative Generalized Myasthenia Gravis: A Report of Three Patients.
- Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases.
- The intricate dance of non-coding RNAs in myasthenia gravis pathogenesis and treatment.
- Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases.
- Paraneoplastic syndrome in neuroophthalmology.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Shenyang for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Takayasu arteritis
大动脉炎Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Shenyang for Takayasu arteritis108 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Shenyang for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Ubiquitin-specific peptidase 10 attenuates bleomycin-induced pulmonary fibrosis via modulating autophagy depending on sirtuin 6-mediated AKT/mTOR.
- SCARF2 is a target for chronic obstructive pulmonary disease: Evidence from multi-omics research and cohort validation.
- Expression of S100A9 and KL-6 in common interstitial lung diseases.
Earlier papers (2016–2020)4
- Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
- Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis.
- Targeted regulation of fibroblast state by CRISPR-mediated CEBPA expression.
- [The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases].
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shenyang for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Real-time photoelectric sensing of edaravone for therapeutic efficacy in amyotrophic lateral sclerosis.
- Micro-Doses of DNP Preserve Motor and Muscle Function with a Period of Functional Recovery in Amyotrophic Lateral Sclerosis Mice.
- Targeting mitochondrial Ca2+ uptake for the treatment of amyotrophic lateral sclerosis.
Other diseases
Fabry disease
法布雷病Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Shenyang for Fabry disease85 hospitals in China for Fabry disease
No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shenyang for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Other diseases
IgA nephropathy
IgA 肾病Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Shenyang for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- The efficacy and safety of hydroxychloroquine versus leflunomide in patients with IgA nephropathy: a single-center experience.
- Exploration of Artemisinin Against IgA Nephropathy via AKT/Nrf2 Pathway by Bioinformatics and Experimental Validation.
- Glomerular deposition of fibrinogen predicts good prognosis of IgA nephropathy: a single-center cohort study.
- Vitamin D and hydroxychloroquine reduce renal injury and Ki67 expression in a rat model of IgA nephropathy via TLR4.
Earlier papers (2016–2020)4
- Serum complement C4 is an important prognostic factor for IgA nephropathy: a retrospective study.
- Development and assessment of a predictive nomogram for the progression of IgA nephropathy.
- Differentially expressed long non‑coding RNAs and mRNAs in patients with IgA nephropathy.
- Analysis of the association between Mycobacterium tuberculosis infection and Immunoglobulin A nephropathy by early secreted antigenic target 6 detection in renal biopsies: a prospective study.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Osteogenesis imperfecta
成骨不全症Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shenyang for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Shenyang for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07282353
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingFenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- Phase
- Phase 2/Phase 3
- Started
- 2023-02
- Registry
- NCT05749822
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan’an, Zhengzhou
- RecruitingFenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
- Phase
- Phase 3
- Started
- 2023-02
- Registry
- NCT05751967
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status4
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 2 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 2.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shenyang for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Inherited epidermolysis bullosa
遗传性大疱性表皮松解症Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Shenyang for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa
No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Hereditary angioedema
遗传性血管性水肿Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Shenyang for hereditary angioedema30 hospitals in China for hereditary angioedema
No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Getting in touch
Name card to show staff or a driver
中国医科大学附属第一医院
First Hospital of China Medical University
沈阳
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
First Affiliated Hospital of China Medical University; College of Basic Medical Science and The First Affiliated Hospital; College of Basic Medical Sciences and First Affiliated Hospital; and First Affiliated Hospital of China Medical University